Identification and characterization of a novel folliculin-interacting protein FNIP2

Hisashi Hasumi1, Masaya Baba, Seung-Beom Hong

  • 1Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20894, United States.

Gene
|April 12, 2008
PubMed

Insights

Researchers identified FNIP2, a novel protein interacting with FLCN, crucial for tumor suppression in Birt-Hogg-Dube syndrome. This discovery sheds light on renal cancer mechanisms and potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Birt-Hogg-Dube syndrome involves germline mutations in the BHD/FLCN gene, increasing renal neoplasia risk.
  • Folliculin (FLCN) is a tumor suppressor protein interacting with FNIP1 and AMPK.

Purpose of the Study:

  • Identify and characterize novel FLCN-interacting proteins.
  • Investigate the role of these interactions in FLCN tumor suppressor function.
  • Explore the differential expression of FNIP1 and FNIP2 in renal cell carcinoma.

Main Methods:

  • Protein interaction assays to identify FNIP2 binding to FLCN and AMPK.
  • Analysis of FLCN mutants to assess FNIP2 binding.
  • Quantitative analysis of FNIP1 and FNIP2 transcript expression in normal tissues and renal tumors.

Main Results:

  • A novel FNIP1 homolog, FNIP2, was identified and shown to interact with FLCN and AMPK.
  • FLCN mutants associated with Birt-Hogg-Dube syndrome failed to bind FNIP2.
  • FNIP1 and FNIP2 can form homo- and heteromeric multimers.
  • Opposite expression of FNIP1 and FNIP2 in clear cell renal cell carcinoma; coordinate expression in other RCC subtypes.

Conclusions:

  • FLCN's tumor suppressor function is likely mediated by interactions with both FNIP1 and FNIP2 via its C-terminus.
  • FNIP1 and FNIP2 may function independently or cooperatively with FLCN.
  • Differential expression patterns suggest distinct roles for FNIP1 and FNIP2 in various renal cell carcinoma subtypes.